IRLAB Therapeutics (Sweden) Performance
| IRLAB-A Stock | SEK 1.85 0.14 8.19% |
The company retains a Market Volatility (i.e., Beta) of -1.05, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning IRLAB Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, IRLAB Therapeutics is expected to outperform it slightly. At this point, IRLAB Therapeutics has a negative expected return of -0.2%. Please make sure to check out IRLAB Therapeutics' treynor ratio, skewness, rate of daily change, as well as the relationship between the value at risk and accumulation distribution , to decide if IRLAB Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days IRLAB Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 277 M | |
| Total Cashflows From Investing Activities | -708 K |
IRLAB |
IRLAB Therapeutics Relative Risk vs. Return Landscape
If you would invest 198.00 in IRLAB Therapeutics AB on November 21, 2025 and sell it today you would lose (27.00) from holding IRLAB Therapeutics AB or give up 13.64% of portfolio value over 90 days. IRLAB Therapeutics AB is generating negative expected returns and assumes 3.1123% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than IRLAB, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
IRLAB Therapeutics Target Price Odds to finish over Current Price
The tendency of IRLAB Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.85 | 90 days | 1.85 | about 75.31 |
Based on a normal probability distribution, the odds of IRLAB Therapeutics to move above the current price in 90 days from now is about 75.31 (This IRLAB Therapeutics AB probability density function shows the probability of IRLAB Stock to fall within a particular range of prices over 90 days) .
IRLAB Therapeutics Price Density |
| Price |
Predictive Modules for IRLAB Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as IRLAB Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.IRLAB Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. IRLAB Therapeutics is not an exception. The market had few large corrections towards the IRLAB Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold IRLAB Therapeutics AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of IRLAB Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.38 | |
β | Beta against Dow Jones | -1.05 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | -0.14 |
IRLAB Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of IRLAB Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for IRLAB Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| IRLAB Therapeutics generated a negative expected return over the last 90 days | |
| IRLAB Therapeutics may become a speculative penny stock | |
| IRLAB Therapeutics has high historical volatility and very poor performance | |
| About 39.0% of the company shares are held by company insiders |
IRLAB Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of IRLAB Stock often depends not only on the future outlook of the current and potential IRLAB Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. IRLAB Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 401.9 M |
IRLAB Therapeutics Fundamentals Growth
IRLAB Stock prices reflect investors' perceptions of the future prospects and financial health of IRLAB Therapeutics, and IRLAB Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IRLAB Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (1.69) % | |||
| Operating Margin | (1.68) % | |||
| Current Valuation | 1.74 B | |||
| Shares Outstanding | 51.79 M | |||
| Price To Book | 6.24 X | |||
| Price To Sales | 33.49 X | |||
| Revenue | 207.78 M | |||
| EBITDA | 55.62 M | |||
| Cash And Equivalents | 401.9 M | |||
| Cash Per Share | 2.89 X | |||
| Total Debt | 3.57 M | |||
| Debt To Equity | 2.90 % | |||
| Book Value Per Share | 6.25 X | |||
| Cash Flow From Operations | 128.64 M | |||
| Earnings Per Share | 0.81 X | |||
| Total Asset | 472.45 M | |||
About IRLAB Therapeutics Performance
By analyzing IRLAB Therapeutics' fundamental ratios, stakeholders can gain valuable insights into IRLAB Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IRLAB Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IRLAB Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurological and neuropsychiatric disorders. Its pipeline candidates include IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinsons disease and Parkinson disease psychosis IRL752, a cortical enhancer for the treatment of Parkinson disease dementia and behavioral and psychological symptoms of dementia IRL626, a fast-off D2 antagonist for use in the treatment of schizophrenia P001, a cortical enhancer program for the treatment of attention disorders and IRL448IRL555, a followup Parkinsons disease program. IRLAB Therapeutics is traded on Stockholm Stock Exchange in Sweden.Things to note about IRLAB Therapeutics performance evaluation
Checking the ongoing alerts about IRLAB Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IRLAB Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IRLAB Therapeutics generated a negative expected return over the last 90 days | |
| IRLAB Therapeutics may become a speculative penny stock | |
| IRLAB Therapeutics has high historical volatility and very poor performance | |
| About 39.0% of the company shares are held by company insiders |
- Analyzing IRLAB Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IRLAB Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining IRLAB Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IRLAB Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IRLAB Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IRLAB Therapeutics' stock. These opinions can provide insight into IRLAB Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for IRLAB Stock analysis
When running IRLAB Therapeutics' price analysis, check to measure IRLAB Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRLAB Therapeutics is operating at the current time. Most of IRLAB Therapeutics' value examination focuses on studying past and present price action to predict the probability of IRLAB Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRLAB Therapeutics' price. Additionally, you may evaluate how the addition of IRLAB Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |